• UCLA Health
  • myUCLAhealth
  • School of Medicine
CARE Center

AIDS Institute

CARE Center   |  

CARE Center
  • About Us
    • History
    • Awards & Accomplishments
    • Staff
    • Our Directors
    • Faculty
    • Donate
    • News & Events
  • Patient Care
    • Medical Care Coordination
  • Clinical Trials
    • Immune Modulators Studies
    • HIV Treatment Studies
    • Hepatitis Co-Infection Studies
    • Human Papillomavirus (HPV) Studies
    • Studies for Women
    • Lymphoma Studies
    • Kaposi's Sarcoma Studies
    • Non-AIDS Defining Cancer
    • HIV Prevention
    • Discussion Groups
    • FAQ
    • Testimonials
    • HIV Treatment Studies
    • Immune Modulators
    • Hepatitis Co-infection Studies
    • Anchor Study (HPV)
    • Studies for Women
    • Lymphoma Studies
    • Kaposi's Sarcoma Studies
    • Non-AIDS Defining Cancer
    • HIV Prevention
    • FAQ
    • Testimonials
  • Community
    • Community Advisory Board
    • Partner of the Month
    • Prevention CAB
  • Research
    • Network Support
    • Conferences
  • RSVP
  • Contact Us
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

AIDS Institute

CARE Center   |  

Clinical Trials

Clinical Trials

Clinical Trials

  • HIV Treatment Studies
    • A5359 Long-acting ART
  • Immune Modulators
    • A5370
    • A5377
    • A5369
    • Pennvax Study
  • Hepatitis Co-infection Studies
    • A5360 MINMON
  • Anchor Study (HPV)
  • Studies for Women
  • Lymphoma Studies
  • Kaposi's Sarcoma Studies
  • Non-AIDS Defining Cancer
  • HIV Prevention
    • PrEP for HIV Prevention
    • Team PrEP
  • FAQ
  • Testimonials
  • HIV Treatment Studies
  • Immune Modulators
  • Hepatitis Co-infection Studies
  • Anchor Study (HPV)
  • Studies for Women
  • Lymphoma Studies
  • Kaposi's Sarcoma Studies
  • Non-AIDS Defining Cancer
  • HIV Prevention
  • FAQ
  • Testimonials
  • A5359 Long-acting ART
  1. Home
  2. Clinical Trials
  3. HIV Treatment Studies

HIV Treatment Studies

Share this

Viral suppression remains the main objective of ART (antiretroviral therapy) for HIV-infected individuals. However, achieving an undetectable viral load continues to be a challenge for many individuals. Aong the obstacles that hinder ART success, poor drug adherence is responsible for most episodes of failure to achieve and maintain virologic suppression. Up to 25% of individuals on chronic ART may experience episodes episodes of non-adherence and only 51% of HIV-infected adults in the US are virally supressed (1). This is a suboptimal outcome from both an individual and public health perspective. Thus, improving ART adherence remains of critical importance in HIV treatment.

The UCLA CARE Center is currently enrolling for studies investigating how to improve HIV treatment: 
  • A5359 (Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV) 

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Publications
  • Giving
  • Careers
  • Volunteer
  • Privacy Practices
  • Nondiscrimination
  • Emergency
  • Smoke-Free
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Report Broken Links
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth